Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AtheroGenics drops high dose in Phase III

On Monday, AGIX fell $0.40 (29%) to $1 after the company said it will

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE